GlassScriptPhysician profile
Nathan A Saucier
NPI 1760511646
$21,338.95
in general payments reported to CMS, 2019-2025
48 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,467 · 2020: $3,623 · 2021: $1,559 · 2022: $2,137 · 2023: $1,662 · 2024: $9,444 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $8,194 · Food and Beverage: $3,461 · Consulting Fee: $548 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $304 · Education: $45.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $8,194.45 |
| Food and Beverage | $3,461.17 |
| Consulting Fee | $548.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $304.00 |
| Education | $45.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $8,194.45 | 2023-2024 | Auryon Laser System 100-120 Vac |
| Inari Medical, INC. | $3,240.90 | 2019-2020 | |
| Medtronic, INC. | $1,399.59 | 2022 | |
| Boston Scientific Corporation | $1,166.48 | 2019-2022 | |
| Nxstage Medical, INC. | $1,165.48 | 2022-2025 | Nxstage System One, Liberty Select Cycler |
| Amgen INC. | $566.76 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Ge Healthcare | $548.00 | 2023-2024 | |
| Genzyme Corporation | $436.54 | 2019-2022 | |
| Vifor Pharma, INC. | $407.67 | 2019-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $389.49 | 2019-2025 | Nxstage System One, Velphoro, Korsuva |
| Astrazeneca Pharmaceuticals LP | $385.85 | 2019-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $359.95 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $283.90 | 2019-2025 | Jynarque |
| Horizon Therapeutics Plc | $266.53 | 2019-2023 | Krystexxa |
| Travere Therapeutics, INC. | $262.98 | 2022-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Saucier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.